Abstracts tagged "Interleukins"

Abstract Number: 1747 • ACR Convergence 2023
A Newly Described Cytokine interleukin-40 Is Increased in the Serum of Individuals At-risk of Rheumatoid Arthritis and Induces an Inflammatory Response in Mononuclear Cells
Adela Navratilova¹, Klára Prajzlerová², Nora Růžičková³, Karel Pavelka⁴, Jiri Vencovsky⁵, Ladislav Senolt⁶, Maria Filkova³ and Lucie Andrés Cerezo³, ¹Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Hlavní město Praha, Czech Republic, ²Institute of Rheumatology, Prague, Czech Republic, ³Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ⁴Institut of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Praha, Czech Republic, ⁵Institute of Rheumatology, Prague, Czech Republic, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ⁶Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Praha, Czech Republic
Background/Purpose: Interleukin-40 (IL-40) is a newly described cytokine related to malignancies and immunity function. We have previously shown that IL-40 is up-regulated in early stages…
Abstract Number: 0314 • ACR Convergence 2023
Lack of Systemic Effects from Intra-articular XT-150 for the Treatment of Moderate to Severe Pain Due to OA of the Knee: Safety Results from a Phase 2 Trial
Leonard Kapural¹, Stephen D. Collins², Eric Grigsby³, Mark McBride⁴, Jayson Rieger⁵, Morgan Stokes⁶, Howard Rutman⁶ and Flavia Cicuttini⁷, ¹Center for Clinical Research, Winston-Salem, NC, ²Xalud Therapeutics, Inc., Chicago, IL, ³Neurovations Clinical Research, Napa, CA, ⁴Instat Clinical Research, Chatham, NJ, ⁵PBM Capital, Charlottesville, VA, ⁶Xalud Therapeutics, Inc., Berkeley, CA, ⁷Monash University, Melbourne, Australia
Background/Purpose: This study (NCT04124042) was designed to assess the safety, tolerability, and efficacy of XT-150, a non-viral gene therapy, in adult participants with moderate to…
Abstract Number: 1782 • ACR Convergence 2023
The Stromal-cell Derived Cytokine interleukin-17D Attenuates Joint Inflammation
Jia (Sijia) Chen¹, Catherine Manning¹, Nataliya Yeremenko², Jae-Hyuck Shim³, Daniel Montoro⁴, Dominique Baeten⁵ and Ellen Gravallese⁶, ¹Brigham and Women's Hospital, Boston, MA, ²Amsterdam University Medical Centers, Amsterdam, Netherlands, ³University of Massachusetts Chan Medical School, Worcester, MA, ⁴TenSixty Biosciences, Boston, MA, ⁵UCB Pharma, Slough, United Kingdom, ⁶Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: The interleukin-17 (IL-17) family of cytokines consists of 6 evolutionarily conserved cytokines, IL-17A-F. Of these, IL-17A, B, C, and F play diverse roles in…
Abstract Number: 0445 • ACR Convergence 2023
Comparison of the Efficacy, Safety and Immunogenicity of a Proposed Biosimilar MSB11456 with Tocilizumab Reference Product in Moderate-to-severe Rheumatoid Arthritis: Results of a Randomized Double-blind Study
Anna Zubrzycka-Sienkiewicz¹, Maria Misterska-Skora², Małgorzata Socik Pojawa³, Kamilla Klama⁴, Martin Ullmann⁵, Corinne Petit-Frere⁵, Andras Illes⁵, Peter Baker⁵, Joëlle Monnet⁵ and Jan Brzezicki⁶, ¹Reumatika - Centrum Reumatologil, Warsaw, Poland, ²Centrum Medyczne Oporów, Wrocław, Poland, ³MICS Centrum Medyczne Warszawa, Warsaw, Poland, ⁴Solumed Centrum Medyczne, Poznań, Poland, ⁵Fresenius Kabi SwissBiosimilars, Eysins, Switzerland, ⁶Centrum Kliniczno Badawcze, Elbląg, Poland
Background/Purpose: Tocilizumab is an anti‑interleukin‑6 receptor monoclonal antibody indicated for treating rheumatoid arthritis (RA) and other inflammatory diseases. MSB11456 is a proposed biosimilar to US‑licensed…
Abstract Number: 1920 • ACR Convergence 2023
A Phase Ib/II Randomized, Double-blind, Placebo-controlled Study of Novel anti-IL-17A Monoclonal Antibody JS005 in Patients with Moderate to Severe Psoriasis
Lin Cai¹, Zhanglei Mu², Xiaohua Tao³, Litao Zhang⁴, Chunlei Zhang⁵, Yumei Li⁶, Guoqiang Zhang⁷, Furen Zhang⁸, Xiuqin Dong⁹, Chengxin Li¹⁰, Aijun Chen¹¹, Zhuning Wu¹², Yuxian Zhu¹², Mengqi Zhang¹², Jiangnian Liu¹² and Jianzhong Zhang¹, ¹Peking University People’s Hospital, Beijing, China, ²Peking University People's Hospital, Beijing, China, ³Zhejiang Provincial People’s Hospital, Hangzhou, China, ⁴Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, Tianjin, China, ⁵Peking University Third Hospital, Beijing, China, ⁶Affiliated Hospital of Jiangsu University, Suzhou, China, ⁷The First Hospital of Hebei Medical University, Shijiazhuang, China, ⁸Shandong Dermatology Hospital, Jinan, China, ⁹Guangdong Provincial People’s Hospital, Guangzhou, China, ¹⁰Chinese PLA General Hospital, Beijing, China, ¹¹The First Affiliated Hospital of Chongqing Medical University, Chongqing, China, ¹²Shanghai Junshi Biosciences, Shanghai, China
Background/Purpose: JS005 is a novel anti-IL-17A monoclonal antibody with unique patented complementarity-determining region (CDR) sequences. This Phase Ib/II study (NCT05344248) aimed to evaluate the safety,…
Abstract Number: 0779 • ACR Convergence 2023
Influence of Sex on the Persistence of Different Classes of Targeted Therapies for Psoriatic Arthritis: A Cohort Study of 14,778 Patients from the French Health Insurance Database (SNDS)
Laura PINA VEGAS¹, Laetitia Penso², Emilie Sbidian³ and pascal claudepierre⁴, ¹Henri Mondor University Hospital (APHP), Rheumatology Department, Créteil, France, ²Université Paris Est Créteil, Créteil, France, ³Hôpital Henri Mondor, Université Paris Est Créteil, Créteil, France, ⁴Universitary Henri Mondor Hospital, Creteil, France
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous condition and sex differences in phenotypic presentation, disease trajectory, and treatment response have been reported. Nevertheless, it remains…
Abstract Number: 2156 • ACR Convergence 2023
Efficacy of Olokizumab in Comorbid Depressive Disorder in Patients with Rheumatoid Arthritis: Preliminary Results of a Study
Vibeke Strand¹, Tatiana Lisitsyna², Anton Abramkin², Dmitry Veltishchev³, Olga Seravina³, Oksana Kovalevskaya³, Anastasia Borisova⁴, Sofia Kuzkina⁵, Vasily Ignatiev⁵ and EVGENY NASONOV⁶, ¹Stanford University, Portola Valley, CA, ²V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia, ³Moscow Research Institute of Psychiatry branch of Serbsky National Medical Research Center for Psychiatry and Narcology of the Ministry of Health, Moscow, Russia, ⁴Moscow Research Institute of Psychiatry branch of Serbsky National Medical Research Center for Psychiatry and Narcology of the Ministry of Health, Mosocw, Russia, ⁵R-Pharm, Moscow, Russia, ⁶Scientific Research Institute of Rheumatology, Moscow, Russia
Background/Purpose: Interleukin-6 (IL) plays an important role in the pathogenesis of comorbid rheumatoid arthritis (RA) depression, and IL-6 inhibitors used to treat RA patients may…
Abstract Number: 0818 • ACR Convergence 2023
Efficacy of XT-150, a Novel Non-Viral Gene Therapy Delivering IL-10v, on Moderate to Severe Pain Due to Osteoarthritis of the Knee: Results of a Phase 2 Trial
Eric Grigsby¹, Stephen D. Collins², Leonard Kapural³, Mark McBride⁴, Jayson Rieger⁵, Morgan Stokes⁶, Howard Rutman⁶ and Flavia Cicuttini⁷, ¹Neurovations Clinical Research, Napa, CA, ²Xalud Therapeutics, Inc., Chicago, IL, ³Center for Clinical Research, Winston-Salem, NC, ⁴Instat Clinical Research, Chatham, NJ, ⁵PBM Capital, Charlottesville, VA, ⁶Xalud Therapeutics, Inc., Berkeley, CA, ⁷Monash University, Melbourne, Australia
Background/Purpose: Interleukin (IL)-10 is a regulator of cytokine activity and has the potential to restore homeostasis in osteoarthritis (OA) of the knee. Unfortunately, relatively short…
Abstract Number: 2241 • ACR Convergence 2023
Guselkumab Efficacy in Active Psoriatic Arthritis Patients with or Without Hyperuricemia: Post-hoc Analysis of Two Phase 3, Randomized, Double-blind, Placebo-Controlled Studies
Renaud FELTEN¹, Laura Widawski², Lionel Spielman², Jacques-Eric Gottenberg³, Pierre-Marie Duret², Emmanouil Rampakakis⁴, Mohamed Sharaf⁵, Caren Constantin⁶, vincenza campana⁶ and Laurent Messer⁷, ¹Hôpital de Hautepierre, Strasbourg, France, ²Hôpitaux civils de Colmar, Colmar, France, ³Rheumatology Department, Strasbourg University Hospital, Strasbourg, France, ⁴JSS Medical Research, Saint-Laurent, QC, Canada, ⁵Immunology, Janssen MEA, Dubai, United Arab Emirates, ⁶Janssen Cilag Medical Affairs, Issy les Moulineaux, France, ⁷Laboratoire Interdisciplinaire en études culturelles (LinCS), Strasbourg, France
Background/Purpose: Patients (pts) with psoriasis (PsO) or PsA are at increased risk for developing gout; and hyperuricemia (HU) prevalence is higher in PsO/PsA pts than…
Abstract Number: 0909 • ACR Convergence 2023
Rab4A Controls the Depletion of IL-2 in CD4+ T Cells via Enhanced CD38 Expression: Potential Involvement in Proinflammatory Lineage Development in Systemic Lupus Erythematosus
Joy Park¹, Xiaojing Wang², Aparna Godavarthy¹, Akshay Patel², Krakko Daniel¹, Jessica Nolan¹, Joanne Chilton¹, Bryan Blaker¹ and Andras Perl³, ¹Upstate Medical University, Syracuse, NY, ²SUNY Upstate Medical University, Syracuse, NY, ³SUNY, Syracuse, NY
Background/Purpose: HRES-1/Rab4 (Rab4A) is a small GTPase that is overexpressed in SLE patient T cells1,2, mediates the enhanced recycling of CD3 and CD4 cell surface…
Abstract Number: 2245 • ACR Convergence 2023
Drug Survival of Risankizumab vs Other Biologics After 13 Months of Treatment Among Patients with PsA in the Multicountry Postmarketing Observational VALUE Study
Lars Erik¹, Kim A Papp², Andrew Östör³, Vassilis Stakias⁴, Tshepiso Madihlaba⁴, Ralph Lippe⁵, Ran Liu⁴ and Diamant Thaçi⁶, ¹Bispebjerg-Frederiksberg Hospital, Vedbæk, Denmark, ²Alliance Clinical Research and Probity Medical Research, Waterloo, and University of Toronto, Toronto, ON, Canada, ³Monash University & Emeritus Research; Australian National University, Melbourne, Australia, ⁴AbbVie, Inc., North Chicago, IL, ⁵AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany, ⁶Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany
Background/Purpose: Risankizumab (RZB) is an optimized IL-23 inhibitor (IL-23i) currently approved for the treatment of plaque psoriasis (PsO), PsA, and Crohn's disease. In a post…
Abstract Number: 0937 • ACR Convergence 2023
IL-4+ and IFN-α+ Profibrotic T Cells Aggravate Systemic Sclerosis via STIM1/STING Signaling in SKG Mice
Ji Won Yang¹, Kun Hee Lee², Jin Seok Woo², Ha Yeon Jeong², JeongWon Choi², Eui-Jong Kwon¹, Mi-La Cho² and Sung-Hwan Park¹, ¹Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ²Rheumatism Research Center, Catholic Research Institute of Medical Science, College of Medicine, The Catholic University of Korea, Seoul, South Korea
Background/Purpose: Systemic sclerosis (SS), also known as scleroderma, is a chronic autoimmune disease caused by inflammation, tissue fibrosis, and vasculopathy. Although the pathological mechanisms of…
Abstract Number: 2254 • ACR Convergence 2023
The Effects of Interleukin 17 Inhibitors on Major Adverse Cardiovascular Events in Patients Naïve to Biologic Agents with Psoriasis or Psoriatic Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Ruoning Ni¹, Jiayi Zheng², Ruru Guo³ and Bharat Kumar⁴, ¹University of Iowa Hospitals and Clinics, Coralville, IA, ²The Wright Center for Graduate Medical Education, Scranton, PA, ³Department of Rheumatology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, ⁴University of Iowa Hospitals and Clinics, Iowa City, IA
Background/Purpose: The aim of this systematic review is to determine the effects of IL-17 inhibitors on major adverse cardiovascular events (MACEs) in patients with psoriasis…
Abstract Number: 1266 • ACR Convergence 2023
The Anti-inflammatory Effect of High-density Lipoprotein Is Blunted by Delivery of Altered MicroRNA Cargo to Macrophages in Patients with Rheumatoid Arthritis
Qiong Wu, Quanhu Sheng, Danielle Michell, Marisol Ramirez-Solano, Olivia Posey, Anastasiia Phothisane, Shahensha Shaik, Kasey Vickers and Michelle Ormseth, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: High-density lipoprotein (HDL) has well-characterized anti-atherogenic cholesterol efflux and antioxidant functions. Another function of HDL uncharacterized in RA is its ability to transport microRNAs…
Abstract Number: 2447 • ACR Convergence 2023
Interleukin-6 Activates Glial Cells and Induces Cognitive Dysfunction in Murine Neuropsychiatric Lupus
Joshua Reynolds¹, Michelle Huang¹, Myriam Meineck², Tamara Möckel², Andreas Schwarting² and Chaim Putterman¹, ¹Albert Einstein College of Medicine, Bronx, NY, ²University Medical Center of the Johannes Gutenberg University of Mainz, Mainz, Germany
Background/Purpose: Up to 50% of SLE patients experience neuropsychiatric involvement (neuropsychiatric lupus, or NPLSE) in the form of cognitive deficits, memory loss, depression, and anxiety.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].